Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Phibro Animal Health Corp. PAHC

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.5B
▲ 17.1% YoY
$99.7M
▲ 106.6% YoY
$9.9M
▼ 76.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Phibro Animal Health Corporation develops, manufactures and markets a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. It manages its business in three segments: Animal Health, Mineral Nutrition, and Performance Products, each with its own dedicated management and sales team. The Animal Health business develops, manufactures and markets about 340 product lines, including antibacterials, anticoccidials and related products, nutritional specialty products, and vaccines. The Mineral Nutrition business manufactures and markets approximately 380 formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States. As of June 30, 2025, it had approximately 2,475 employees in 70 locations spanning 36 countries.

Written from the business description in PHIBRO ANIMAL HEALTH CORP's annual report to the U.S. Securities and Exchange Commission, filed 27 August 2025. Every sentence was checked against that document before publication.

Growth

USD 1.5B
Revenue, FY2025 · full 15-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.5 · Net income 0.1
1B2B
201120142017202020232025
Compound annual growth
+15.8%
+12.7%
+7.3%
+45.2%
+12.9%
+1.9%
+44.2%
+12.6%
+0.0%
+0.0%
+0.0%
+0.0%
+2.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.7% a year over the five years to FY2025 — but profit grew faster: net income at +12.9%, earnings per share at +12.6%.

The share count rose from 0.02B to 0.02B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

7 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 12.8% · Net 6.6%
5%10%
201120182025
ROE
FY2025 · ROE 29.7%
100%200%
201120182025
Three returns, three denominators.

Each USD of equity produced 30 cents of profit this year.

Cash & shareholders

USD 19.5M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 9.9
30M60M-15M-30M
201120182025
Net buybacks $M Dividends $M
FY2025 · Dividends 19.5 · Net buybacks ·
10M20M
20122014201620182020202220242025

USD 19.5M in dividends — 20% of the year's profit went back to shareholders.

Total assetsUSD 1.5B
EquityUSD 385.5M
CashUSD 61.4M
Current ratio2.96×

Equity funds 26% of total assets.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PAHC, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B1.51.31.01.00.90.80.80.80.80.80.80.70.70.70.7
Operating income $B0.20.10.10.10.10.10.10.10.10.10.10.10.10.10.0
EBITDA $B0.20.20.10.10.10.10.10.10.10.10.10.10.10.10.1
Income tax $B0.00.00.00.00.00.00.00.00.00.0−0.00.00.0−0.00.0
Net income $B0.10.00.00.00.00.10.00.10.10.10.10.1−0.00.00.0
Free cash flow $B0.00.00.0−0.0−0.00.00.00.00.10.10.00.0−0.0−0.00.0
EPS, diluted $2.431.190.060.811.211.340.831.351.611.612.071.51−0.100.820.23
Dividend / sh $0.480.480.480.480.480.480.480.460.400.400.400.400.820.10◌
Payout %2040805604036583425241926−79912—
ROE %29.717.80.912.019.625.516.627.338.653.5137.8269.2———
Shares out B0.020.020.020.020.020.020.020.02◌◌◌◌◌0.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 73 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011. Four checks were skipped: revenue is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
Data on record since2011

Share this section

Download image